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Abstract
Background: The profile of subjects undergoing percutaneous mitral balloon valvuloplasty
(PMBV) in developed countries has shifted toward the elderly. In the group of elderly patients
long-term results after PMBV, as well prognostic factors that may improve patient selection for
this procedure have not been fully elucidated. Aim of the study was to evaluate the safety and
efficacy of PMBV for the treatment of mitral stenosis in patients older than 65.
Methods: The studied group consists of 132 consecutive patients aged > 65, who underwent
PMBV. All PMBV procedures were performed by the antegrade transvenous approach using
the Inoue balloon system.
Results: Procedural success, defined as mitral valve area ≥ 1.5 cm2 and mitral regurgitation
£ 2+, was obtained in 105 (79.5%) patients. Mean follow-up was 6.25 ± 4.33 years. Echo
score > 8 and higher mean mitral valve gradient were significant independent predictors of
inadequate immediate result. Survival curves showed that for the whole studied group after
PMBV the 3-, 5-, and 10-year overall survival rates were significantly better in patients with
left atrium diameter £ 5.0 cm before intervention (95.4%, 91.3% and 80.5% vs. 89.6%,
69.5%, and 53.7%, respectively; p = 0.002). Survival free of mitral valve intervention or heart
failure ≥ NYHA III was significantly better for patients with good immediate result and mean
pulmonary artery pressure after PMBV < 25 mm Hg.
Conclusions: PMBV is safe and efficacious in elderly patients with symptomatic mitral
stenosis. Long-term results are good and related mainly to the quality of the procedure. (Cardiol J
2013; 20, 1: 44–51)
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Introduction
Percutaneous mitral balloon valvuloplasty
(PMBV) is safe and effective for selected sympto-
matic patients with mitral valve stenosis [1, 2]. In
developed countries during the last decades the
profile of subjects undergoing this procedure has
shifted toward the elderly [3, 4]. These patients in
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many cases have less favorable mitral valve anato-
my, but because of comorbidities their surgical risk
is high. In effect, many elderly patients are referred
for less invasive treatment, despite suboptimal
valve anatomy [5–7]. Careful patient selection is
crucial for successful PMBV [8–10]. Age has been
found a predictor affecting late results in a series
of patients after balloon commissurotomy, but data
from previous studies are inconsistent [2, 10, 11].
Furthermore, the long-term results after PMBV as
well prognostic factors that can improve patient
selection for this procedure have been not fully elu-
cidated in the elderly [11–14]. To address this is-
sue we have conducted an observational study in
a group of consecutive mitral stenosis patients
older than 65 treated with PMBV.
Methods
Patient population
There were 1564 PMBV procedures performed
at the Warsaw Institute of Cardiology from Septem-
ber 1988 through December 2007. The studied
group consists of 132 patients, who at the time of
the procedure were over 65 years of age. There
were 114 (86.4%) female and 18 (13.6%) male pa-
tients. Their mean age was 68.8 ± 3.63 years (me-
dian 68, range 65–80).
Indications for PMBV were symptomatic
(≥ NYHA class II) mitral valve stenosis with mitral
valve area (MVA) < 1.5 cm2. Patients were selected
for PMBV based on suitable mitral valve morpho-
logy. Percutaneous treatment was not recommen-
ded if any of the following were present: flexural
rigidity of valve leaflets, extensive valve calcifica-
tions; changes in the subvalvular apparatus, mitral
valve regurgitation > 2+, presence of thrombus in
the left atrium. These subjects were referred for
surgical valve replacement or in cases of high sur-
gical risk medical therapy was recommended.
Thirty-four (25.8%) patients had previous sur-
gical and 2 (1.5%) percutaneous mitral commissuro-
tomy. Atrial fibrillation was present in 91 (68.9%)
patients. Each patient underwent 2-dimensional
echocardiographic examination before PMBV and
24 h to 48 h after the procedure. Echocardiogra-
phic score was used to assess the severity of patho-
logical lesions in the valve and subvalvular appara-
tus [15]. The gradient across mitral valve was mea-
sured using Doppler method, and MVA was deter-
mined by planimetry. Left atrium diameter was
measured from the parasternal long-axis view at
end-systole. The mean ECHO score was 7.49 ±
± 1.46 (median 8, range 3–11). Thirty-five (26.5%)
patients had ECHO score > 8. The mean left atrium
diameter before PMBV was 5.2 ± 1.1 cm (median
5.0 cm).
The study was approved by the local Ethics
Committee and all patients gave written informed
consent to undergo the procedure and for the use
of the collected data for scientific purposes.
Technique of PMBV
All PMBV procedures were performed by the
antegrade transvenous approach using the Inoue
balloon system (Toray Industries, Inc., Tokyo, Ja-
pan). Mean balloon diameter used during the pro-
cedure was 27.7 ± 1.19 mm. Hemodynamic mea-
surements including pulmonary artery pressure,
left atrial pressure, left ventricular pressure as well
as cardiac output were done prior to and after val-
vuloplasty. Mitral regurgitation was assessed dur-
ing left ventriculography using the Sellers classifi-
cation [16].
Data collection and follow-up
Clinical assessment was carried out 6 months
after repeat PMBV and annually thereafter. Clinical
evaluation was done by direct interview during a cli-
nic visit. Patients who failed to report for follow-up
were contacted by phone or responded to mailed
questionnaires. If necessary, local physicians, “con-
tact person” or family member were contacted to
obtain detailed information. In 8 cases, data were
obtained from the Death Registry of the Ministry of
Internal Affairs and Administration of Poland.
End points
The endpoints assessed were: a) all-cause sur-
vival, b) survival considering the need for mitral
valve intervention (surgery or repeat PMBV),
c) survival considering only cardiovascular death
and the need for mitral valve intervention, d) “good
functional result” — survival free of mitral valve
intervention or heart failure ≥ NYHA III.
Statistics analysis
Categorical variables were presented as per-
centages and compared with the c2 test. Continu-
ous variables were expressed as means ± standard
deviations. For comparison of continuous parame-
ters before and after the procedure a paired Student
t-test or Wilcoxon test was used (depending on data
distribution).
All baseline characteristics were tested inde-
pendently by univariate logistic regression as
a potential predictor of immediate procedural suc-
cess. Variables which achieved a significance level
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of p < 0.1 were incorporated into a multivariate
logistic regression model. To identify the best cut-
off point of mean mitral valve gradient (MVG) for
predicting immediate procedural success the re-
ceiver operating characteristic (ROC) curve was
constructed. Next, depending on the severity of
ECHO score and mean MVG patients were divided
into 4 groups: 1) ECHO score £ 8 and mean MVG
£ 10 mm Hg, 2) ECHO score £ 8 and mean MVG
> 10 mm Hg, 3) ECHO score > 8 and mean MVG
£ 10 mm Hg, 4) ECHO score > 8 and mean MVG
> 10 mm Hg. The percentage of patients with good
immediate result was calculated in each group.
Separate univariate Cox logistic regression
analyses were performed for all baseline and post-
procedural variables. Potential independent predic-
tors of death and combined endpoints were identi-
fied by means of step-down modeling in a multivari-
able Cox model adjusting for baseline variables with
a significance of less than 0.1 in univariable analysis.
Kaplan-Meier method was used to determine total
survival and event-free survival curves. Groups
were compared using the log-rank test. Differences
were considered significant at p < 0.05. Statistical
analyses were performed with the SPSS (version 9.0)
statistical package.
Results
Immediate results
PMBV was completed in all 132 patients.
Table 1 presents baseline patient characteristics
and measurements performed during the proce-
dure. PMBV resulted in an increase of MVA and
cardiac output, and a decrease of transmitral gradi-
ent, mean pulmonary artery pressure (mPAP) and
mean left atrial pressure. The median mPAP after
PMBV was 25 mm Hg. Procedural success, defined
as MVA ≥ 1.5 cm2 and mitral regurgitation £ 2+,
was obtained in 105 (79.5%) subjects. An inadequate
immediate result was related to mitral regurgita-
tion ≥ 3+ in 10 (7.6%) patients, MVA < 1.5 cm2 in
16 (12.1%) patients, and MVA < 1.5 cm2 with mi-
tral regurgitation ≥ 3+ in 1 (0.8%) patient.
Of the 5 variables found significant in univari-
ate analysis only ECHO score > 8 and higher mean
MVG remained statistically significant predictors of
inadequate immediate result in multivariate analy-
sis (Table 2). The best cut-off point of mean MVG
predicting procedural success was 10.5 mm Hg. The
rate of procedural success was significantly higher
in the group of 86 patients with ECHO score £ 8
and mean MVG £ 10 mm Hg than those (12 pa-
tients) with ECHO score > 8 and MVG > 10 mm Hg
(86% vs. 41.7%, p = 0.001) (Fig. 1).
There were two severe procedure-related
complications. One patient required emergency
mitral valve surgery due to significant mitral regur-
gitation. Another patient experienced perforation of
the inferior vena cava while removing the Inoue
catheter post dilation. She underwent urgent vas-
cular surgery followed by disseminated intravascu-
lar coagulation and death. There were no cases of
pericardial tamponade or thromboembolism.
Table 1. Hemodynamic and echocardiographic findings before and after percutaneous mitral balloon
valvuloplasty (PMBV).
Before PMBV After PMBV P
Mean transmitral gradient (Doppler) [mm Hg] 7.74 ± 3.76 4.15 ± 1.89 < 0.001
Maximal transmitral gradient (Doppler) [mm Hg] 16.09 ± 5.46 10.03 ± 3.61 < 0.001
Mitral valve area (planimetry) [cm2] 1.19 ± 0.28 1.83 ± 0.38 < 0.001
Pulmonary artery systolic pressure [mm Hg] 48.47 ± 15.13 39.53 ± 13.88 < 0.001
Mean pulmonary artery pressure [mm Hg] 31.55 ± 10.24 26.47 ± 9.12 < 0.001
Transmitral gradient (hemodynamic) [mm Hg] 12.29 ± 5.24 4.84 ± 3.09 < 0.001
Cardiac output [L/min] 4.37 ± 1.14 4.72 ± 1.36 < 0.001
Mean left atrial pressure [mm Hg] 23.2 ± 7.18 17.45 ± 7.62 < 0.001
Mitral regurgitation (Seller’s class):
0 76 (57.6%) 63 (47.7%)
1 46 (34.8%) 43 (32.6%)
2 10 (7.6%) 15 (11.4%) < 0.001
3 0 10 (7.6%)
4 0 1 (0.8%)
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Long-term follow-up
The mean follow-up was 6.25 ± 4.33 years. Pa-
tient survival, need for mitral valve replacement or
repeat PMBV and functional status are presented
in Figure 2.
Survival
One patient died due to periprocedural compli-
cations described above. Additional 32 patients died
during follow-up: 18 due to cardiovascular reasons,
4 due to unknown causes and 10 due to non-cardiac
causes (2 — liver cirrhosis, 4 — cancer, 1 — renal
failure, 2 — pneumonia, 1 — acute pancreatitis).
Four deaths of unknown cause were considered car-
diovascular related.
The indpendent predictors of all-cause morta-
lity were higher age (OR 1.14, 95% CI 1.02–1.26,
p = 0.017) and larger left atrium diameter before
PMBV (OR 1.29, 95% CI 1.05–1.57, p = 0.013).
Table 2. Predictors of good immediate result of percutanoeus mitral balloon valvuloplasty in univariate
and multivariate analysis.
Variable Odds ratio 95% confidence interval P
Univariate analysis
Mean mitral gradient (Doppler) 1.19 1.06–1.32 0.028
Max. mitral gradient (Doppler) 1.10 1.02–1.19 0.018
Echocardiographic score > 8 2.86 1.18–7.14 0.020
Systolic pulmonary artery pressure 1.03 1.01–1.06 0.035
Mean pulmonary artery pressure 1.04 1.01–1.09 0.033
Multivariate analysis
Mean mitral gradient (Doppler) 1.16 1.05–1.30 0.005
Echocardiographic score > 8 2.56 1.01–6.67 0.049
Mean MVG 10 mm Hg£
ECHO score 8£
Mean MVG > 10 mm Hg
ECHO score > 8
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
74/86
(86%) 18/23
(78.3%)
5/12
(41.7%)
8/11
(71.1%)
132 patients after PMBV
33 died99 alive
16 MVR
7 died63 NYHA II£ 6 NYHA II£ 3 NYHA II≥26 NYHA III≥ NYHA III
26 died89 medical therapy only 1 rePMBV
Figure 1. Relationship between the echocardiographic
score (ECHO score), mean pre-percutaneous balloon
mitral valvuloplasty mitral valve gradient (MVG) and
procedural success.
Figure 2. Patient survival, need for mitral valve replacement (MVR) or repeat percutaneous mitral balloon valvuloplasty
(PMBV) and functional status after PMBV; NYHA — New York Heart Association.
48
Cardiology Journal 2013, Vol. 20, No. 1
www.cardiologyjournal.org
Kaplan-Meier survival curves showed that for
the whole studied group after PMBV, the 3-, 5-, and
10-year overall survival rates were 92.8%, 81.6% and
68.4%, respectively and were significantly better in
patients with left atrium diameter £ 5.0 cm before
intervention (95.4%, 91.3% and 80.5% vs. 89.6%,
69.5%, and 53.7%, respectively; p = 0.002; Fig. 3).
Survival considering mitral valve intervention
Sixteen patients underwent mitral valve repla-
cement after PMBV. Ten had a suboptimal imme-
diate PMBV result (6 patients with mitral regurgi-
tation ≥ 3+ and 4 with MVA < 1.5 cm2). Six other
patients developed mitral valve restenosis after suc-
cessful PMBV. In addition, 1 patient underwent
repeat PMBV due to restenosis 4 years after initial
procedure.
The independent predictors of all-cause death
and mitral valve replacement were larger left atrial
diameter before PMBV (OR 1.23, 95% CI 1.01–1.51,
p = 0.044) and higher mPAP after PMBV (OR 1.06,
95% CI 1.02–1.10, p = 0.003).
Suboptimal immediate result was a predictor
of death and mitral valve intervention in univariate
analysis only (OR 2.64, CI 1.28–5.42, p = 0.006), in
multivariate analysis it did not achieve statistical
significance.
Survival considering mitral valve intervention
and repeat PMBV for the entire group at 3, 5, and
10-years was 87.5%, 71.9%, 57.1%, respectively.
The survival was significantly better in patients
with mPAP after PMBV < 25 mm Hg (92.0% vs.
82.3% at 3, 79.8% vs. 60.9% at 5 and 68.4% vs.
37.0% at 10 years, p = 0.003) (Fig. 4A) and good
immediate result (89.0% vs. 81.0% at 3, 76.9%
vs. 50.9% at 5, and 62.3% vs. 25.5% at 10 years,
p = 0.002) (Fig. 4B).
Taking into account cardiovascular death and
mitral valve interventions only, the independent
predictors of worse outcome were suboptimal im-
mediate result (OR 2.94, CI 1.28–6.67, p = 0.011),
previous commissurotomy (OR 2.38, CI 1.15–4.93,
p = 0.020), and higher mPAP after PMBV (OR 1.05,
CI 1.00–1.09, p = 0.037).
Good functional result
Sixty-three (47.7%) patients were alive, with-
out mitral valve intervention and in NYHA class I
0.0
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p = 0.002
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Figure 3. Kaplan-Maier survival curves after percutane-
ous balloon mitral valvuloplasty for patients with left
atrium (LA) £ 5 cm and > 5 cm.
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Figure 4. Kaplan-Maier event-free (death, mitral valve
replacement, redoPMBV) survival curves for patients
with mean pulmonary artery pressure (mPAP) after per-
cutaneous balloon mitral valvuloplasty < 25 mm Hg and
≥ 25 mm Hg (A) and for patients with good and inade-
quate immediate result (B).
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or II (good functional result) when follow-up was
concluded.
The independent predictors of death, mitral
valve intervention or severe heart failure (NYHA
III or IV) were suboptimal immediate result (OR
1.92, CI 1.02–3.57, p = 0.045), higher age (OR 1.13,
CI 1.06–1.22, p < 0.001), and higher mPAP after
PMBV (OR 1.04, CI 1.1–1.07, p = 0.018).
Survival with good functional result for the
entire group at 3, 5, and 10-years was 81.8%, 64.7%
and 42.0%, respectively, and was significantly better
for patients with mPAP after PMBV < 25 mm Hg
(90.7% vs. 71.1% at 3, 74.0% vs. 52.7% at 5 and 54.6%
vs. 23.9% at 10 years, p = 0.001) (Fig. 5A) and good
immediate result (84.1% vs. 72.2% at 3, 69.4%
vs. 45.4% at 5, and 48.4% vs. 13.0% at 10 years,
p < 0.001) (Fig. 5B).
Discussion
The results of this study show that PMBV is
safe and effective also in patients older than 65 years
of age. The complication rate in this age group was
similar to that reported in other studies [11–13].
Understandably, it has been shown that the num-
ber and probability of complications tends to in-
crease along with increasing age [5, 17, 18]. From
the technical point of view the procedure is com-
paratively age-independent. However, older pa-
tients often have more vessel tortuosity, larger ro-
tated heart and large atria, making the procedure
more demanding even for an experienced operator.
The immediate results obtained in this study
are good. The percentage of patients in whom
a good immediate result was achieved is even larg-
er than in previous studies with similar definitions
of procedural success [12–14, 19, 20]. It may be the
consequence of the fact that patients included in this
study had somewhat less advanced valve patholo-
gy compared to other studies. Mean ECHO score
in this cohort was 7.5 and only 25% of patients had
an ECHO score above 8. In contrast, in the work of
Tuzcu et al. [12], who analyzed a cohort of 99 pa-
tients older than 65, the mean ECHO score was 9.2,
and two-thirds of patients had a score above 8. Kra-
suski et al. [14] in a group of 55 patients > 65 years
old also report a high ECHO score of 9.9. On the
other hand, in one German study [17] only 12% of
146 patients older than 70 treated with PMBV had
an ECHO score > 8.
The technique of the procedure could also in-
fluence immediate results. In all patients analyzed
in this report Inoue balloon was used, while in the
report by Tuzcu et al. [12] a double-balloon tech-
nique was employed. According to Iung et al. [13]
the Inoue balloon technique “tended to yield bet-
ter immediate results”. However, in one random-
ized study the Inoue and double-balloon techniques
were equally effective [21].
In our whole cohort of patients the elderly sub-
group constituted less than 10% of all PMBV treat-
ed patients, whereas in the cohorts from the Unit-
ed Kingdom or United States this age group con-
stituted around 30% of all treated patients [5, 12].
However, in papers published by French and Ger-
man researchers on large cohorts (1285 and 1123,
respectively), the percentages of elderly reported
(defined as older than 70 in those studies) were sim-
ilar to ours (5.8% and 13%, respectively). The varia-
Figure 5. Good functional results (event-free survival in
New York Association Class I or II) for patients with
mean pulmonary artery pressure (meanPAP) after
percutaneous balloon mitral valvuloplasty (PMBV)
< 25 mm Hg and ≥ 25 mm Hg (A) and for patients with
good and inadequate immediate result (B).
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bility of these percentages likely resembles differ-
ences in the course and treatment of rheumatic dis-
ease [1]. One may speculate that some elderly mi-
tral stenosis patients due to comorbidities and poor
performance status were not referred for any kind
of intervention, whereas patients with lower opera-
tive risk and advanced disease were referred for
mitral valve replacement. PMBV patients from de-
veloping countries are substantially younger [22, 23].
It is of note that in the cohort analyzed in this
study prior commisurotomy patients with mitral
restenosis were comparatively numerous. Earlier
studies have shown that PMBV in these patients is
effective irrespectively of age [24, 25]. However,
in this study, it was the subgroup with higher risk
of cardiovascular death and reintervention.
Two factors significantly affecting the PMBV
immediate result were identified in the present
analysis: ECHO score above 8 and higher pre-pro-
cedure Doppler MVG. In an earlier report an ECHO
score > 8 was independently related to a worse
immediate result of PMBV in a large cohort [2]. In
a group of 44 patients with the age ≥ 75 years pro-
cedural success was greater in patients with ECHO
score £ 8 although significance level was not
achieved [26]. We have not found any data from the
literature indicating that pre-procedure MVG pre-
dicts PMBV result in the elderly. In our analysis
86% of patients with a ECHO score £ 8 and MVG
£ 10 mm Hg experienced a good immediate PMBV
result. This percentage was over twice lower in
the subgroup with a ECHO score > 8 and MVG
> 10 mm Hg. We believe that these two parameters,
measurable during a standard non-invasive echocar-
diographic evaluation, may be of value when con-
sidering treatment options for the individual patient.
The long-term results achieved in the analyzed
cohort are favorable. Age was shown to be an inde-
pendent predictor of all-cause mortality and good
functional result, but not of the combined endpoint
consisting of mortality and mitral valve reinterven-
tion. Previous studies had generally, but not uni-
formly shown that patients over 65 had worse long-
term outcomes than younger patients [14, 27]. Pre-
procedure left atrium (LA) diameter also turned out
to have prognostic significance. On long-term fol-
low-up patients with LA < 5 cm had better surviv-
al than patients with LA ≥ 5 cm. LA diameter and
volume had also been proven an adverse prognos-
tic factor in previous works [27, 28].
On univariate analysis good PMBV immediate
result was a predictor of mitral valve intervention-
-free survival. This, however, was not confirmed on
multivariate analysis. The reason may be a limited
sample size. Also, almost a third of total mortality was
due to non-cardiovascular reasons. Considering only
cardiac mortality and valve reinterventions, good
PMBV immediate result was a strong independent
factor favoring better prognosis. It was also an inde-
pendent prognostic factor of good functional result.
Mean pulmonary artery pressure after PMBV,
reflecting the efficacy of the procedure, was also
a strong independent predictor of better survival
without reintervention. Accepting the median
mPAP post-procedure as the cutoff point, patients
with mPAP < 25 mm Hg fared better with respect
to survival without reintervention and with respect
to good functional result. This finding remains con-
sistent with the study by Meneveau et al. [27],
which demonstrated that patients with mPAP
< 25 mm Hg post PMBV have a better event-free
survival in long-term follow-up.
Limitations of the study
It must be acknowledged that the study has
several limitations. This is a retrospective analysis
with prospective data acquisition. Consecutive mi-
tral stenosis patients older than 65 selected for
PMBV are analyzed. We have no data on patients
that were operated or treated conservatively.
Therefore, we may not extrapolate the results of
this analysis to describe the whole population of
elderly mitral stenosis patients. We have been un-
able to analyze follow-up echocardiographic param-
eters as some data were unavailable. The age cut-
off point selected may also be considered somewhat
arbitrary. In prior studies, researchers accepted
either 65 or 70 years of age for defining the group
of the elderly. We have chosen the age of 65 as per-
haps more universal, although contemporary defi-
nition of the word “elderly” is undoubtedly evolv-
ing. We have not compared the efficacy of PMBV
in different age subgroups either.
Conclusions
PMBV is safe and efficacious in the subgroup of
elderly (over 65) patients with symptomatic mitral
stenosis. Procedural success is most likely in pa-
tients with ECHO score < 8 and lower MVG. Good
immediate PMBV result and post-procedure mPAP
< 25 mm Hg predict better long-term prognosis.
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